Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls
a cross-sectional analytical study
Keywords:
Colitis, ulcerative, Vascular endothelial growth, EndostatinsAbstract
BACKGROUND: Increased angiogenetic activity in inflammatory bowel disease (IBD) has been shown in previous studies. The aim of this study was to evaluate the relationship of serum vascular endothelial growth factor (VEGF) and endostatin levels with clinical features and mucosal expression in patients with ulcerative colitis (UC). DESIGN AND SETTING: Cross-sectional analytical study conducted in a tertiary-level public hospital. METHODS: Serum VEGF and endostatin levels were determined in 82 individuals: 39 with UC, 28 with irritable bowel syndrome (IBS) and 15 healthy controls (HCs), using enzyme-linked immunosorbent assays (ELISA). VEGF and endostatin expressions were studied using immunohistochemistry (IHC). RESULTS: Mean serum VEGF and endostatin levels were significantly higher in patients with UC than in patients with IBS and in HCs (511.9 ± 377.5 pg/ml, 305.0 ± 121.42 pg/ml and 36.1 ± 40.6 pg/ml; P = 0.001 for VEGF; and 155.50 ± 59.8 ng/ml, 116.9 ± 23.8 ng/ml and 102.2 ± 22.4 ng/ml; P < 0.001 for endostatin, respec- tively). There was a positive correlation between serum VEGF and endostatin levels (r = 0.422; P < 0.01). Mean H-scores for VEGF expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma, endothelium and epithelium. Mean H-scores for endostatin expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma and endothelium. There was no endostatin expression in the epithelium. CONCLUSION: Increased endostatin appears to be a defensive reaction to increased VEGF in patients with UC.
Downloads
References
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417-29. PMID: 12167685; doi: 10.1056/NEJMra020831.
Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87(7):1153-5. PMID: 8980221; doi: 10.1016/S0092-8674(00)81810-3.
Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169(6):2014-30. PMID: 17148665; doi: 10.2353/ajpath.2006.051021.
Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):G5-G18. PMID: 17463183; doi: 10.1152/ajpgi.00107.2007.
Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18(5):418-
PMID: 12761641; doi: 10.1007/s00384-003-0495-y.
Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol. 1998;33(5):504-8. PMID: 9648990; doi: 10.1080/00365529850172070.
Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis. 1999;5(1):44-60. PMID: 10028449; doi: 10.1097/00054725-200411000-00021.
Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, et al. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(4):963-70. PMID: 20629092; doi: 10.1002/ibd.21410.
Griga T, Werner S, Köller M, Tromm A, May B. Vascular endothelial growth factor (VEGF) in Crohn’s disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes. Dig Dis Sci. 1999;44(6):1196-201. PMID: 10389696.
Tsiolakidou G, Koutroubakis IE, Tzardi M, Kouroumalis EA. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. Dig Liver Dis. 2008;40(8):673-9. PMID: 18374637; doi: 10.1016/j. dld.2008.02.010.
Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96(3):822-8. PMID: 11280558; doi: 10.1111/j.1572-0241.2001.03527.x.
Ardelean DS, Yin M, Jerkic M, et al. Anti-EGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. Angiogenesis. 2014;17(3):641-59. PMID: 24510304; doi: 10.1007/s10456-014-9421-x.
O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85. PMID: 9008168; doi: 10.1016/S0092-8674(00)81848-6.
Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin’s antiangiogenic signaling network. Mol Cell. 2004;13(5):649-63. PMID: 15023336; doi: 10.1016/S1097-2765(04)00102-9.
Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in ulcerative colitis: a key to impaired healing?Biochem Biophys Res Commun. 2006;350(1):147-50. PMID: 17011522; doi: 10.1016/j.bbrc.2006.09.021.
Deng X, Tolstanova G, Khomenko T, et al. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. J Pharmacol Exp Ther. 2009;331(3):1071-8. PMID: 19762547; doi: 10.1124/jpet.109.158022.
Liou JY, Shyu KG, Lu MJ, et al. Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease. J Formos Med Assoc. 2006;105(5):377-83. PMID: 16638647; doi: 10.1016/S0929-6646(09)60133-9.
Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87(8):971-6. PMID: 1642220.
Yoon JY, Park SJ, Hong SP, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59(4):829-37. PMID: 24352705; doi: 10.1007/s10620-013-2907-3.
Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130(7):2060-73. PMID: 16762629; doi: 10.1053/j.gastro.2006.03.054.
Tolstanova G, Deng X, Khomenko T, et al. Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. Life Sci. 2011;88(1-2):74-81. PMID: 21047522; doi: 10.1016/j.lfs.2010.10.026.
Salem HA, Wadie W. Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis. Sci Rep. 2017;7(1):7139. PMID: 28769047; doi: 10.1038/s41598-017-07280.
